个人简介
Francesca Lorentino医生是IRCCS圣拉斐尔科学研究医院血液病和骨髓移植科的血液病专家兼移植专家,在Fabio Ciceri教授的指导下开展工作。
2011年毕业于圣拉斐尔生命健康大学医学院,2017年获得同一所大学的血液学专业学位。2020年11月起,先后获得米兰比可卡大学公共健康、生物统计学和流行病学博士学位。Lorentino医生多次参与海外实习,曾与巴黎的EBMT急性白血病工作组合作,担任接受同种异体骨髓移植患者的多中心登记研究的主要研究员。
临床上,Lorentino医生主要负责接受过同种异体骨髓移植、基因治疗和细胞治疗(如嵌合抗原T细胞受体[CAR-T细胞])的恶性血液病患者。
作为研究员,Lorentino医生目前参与了以下工作组的临床试验:意大利骨髓移植工作组(GITMO)、急性白血病工作组以及细胞治疗和免疫生物学工作组DELL'EBMT。
她以作者或共同作者的身份在意大利国内外学术期刊上发表了25篇文章,也参与了多个书籍章节的编写。她经常参加意大利国内外的行业会议。
出版物
最新出版物
Microbiome Markers are Early Predictors of Acute GvHD in Allogeneic Hematopoietic Stem Cell Transplant recipients
Blood. 2020 Nov 10:blood.2020007158. doi: 10.1182/blood.2020007158.
Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Front Oncol. 2020 Oct 15;10:572918. doi: 10.3389/fonc.2020.572918. eCollection 2020.
Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia
Leukemia. 2020 May 14. doi:10.1038/s41375-020-0863-4. Online ahead of print.
Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation
Front Immunol. 2020 Feb 25;11:147. doi: 10.3389/fimmu.2020.00147. eCollection 2020.
Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching
Biol Blood Marrow Transplant. 2020 Jun;26(6):1179-1188. doi: 10.1016/j.bbmt.2020.01.013. Epub 2020 Jan 28.
Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Posttransplant Cyclophosphamide
Front. Immunol., 01 October 2019 |
Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft-versus-host disease prediction after unrelated donor hematopoietic cell transplantation
Haematologica. 2020 Apr;105(4):e186-e189. doi: 10.3324/haematol.2019.225177. Epub 2019 Aug 30.
Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission
Am J Hematol. 2018 Oct;93(10):1236-1244. doi: 10.1002/ajh.25231. Epub 2018 Sep 3.
Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide
Leukemia. 2019 Jan;33(1):230-239. doi: 10.1038/s41375-018-0170-5. Epub 2018 Jun 15.
The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis
Blood Advances 2017 1:669-680; doi:
扩展阅读
NK cell recovery after haploidentical HSCT with post-transplant cyclophosphamide: dynamics and clinical implications
Blood 2017 :blood-2017-05-780668; doi:
Post-transplant cyclophosphamide and Sirolimus after Haploidentical HSCT Using a Treosulfan-based myeloablative conditioning and PBSC
Blood. 2016 Sep 15;128(11):1528-31.
Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation
Bone Marrow Transplant. 2016 Sep 26.
Post-transplant cyclophosphamide versus antithymocyte-globulin as graft versus host disease prophylaxis in haploidentical transplant
Haematologica. 2016 Oct 6.